Parse Biosciences introduces workflow for immune repertoire and transcriptome analysis: Seattle Saturday, January 24, 2026, 15:00 Hrs [IST] Parse Biosciences, the leading provider ...

Parse Biosciences launches a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker.

According to Nova One Advisor, the global next-generation sequencing market size is calculated at USD 17.37 billion in 2026 ...

Project LiBRha aims to improve pediatric STS diagnosis and treatment through comprehensive molecular testing and liquid biopsy integration. The initiative involves 18 centers and partnerships with the ...

Caris Life Sciences plans to report its complete fourth quarter and full year 2025 financial results during its earnings call ...

Caris and Everlywell are partnering to launch Caris Detect™, Caris' forthcoming Multi-Cancer Early Detection (MCED) ...

A recent study reveals that bacteria residing within colorectal tumors form distinct ecosystems closely linked to disease progression and patient outcomes. These “tissue-resident” microbes appear to ...

Partnership unites AI and single cell technology to map immune dysfunction and improve drug discovery and development outcomes Parse Biosciences and Graph Therapeutics (Graph) today announced a strate ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the 44th Annual J.P.

Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of ...

New method enables single cell discovery from archived tissue samples, expanding access to translational and clinical research SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of ...